ArticlePharmacology research & perspectives2026
The JAK1/2 Inhibitor Baricitinib Ameliorates Neuroinflammation and Symptoms in an Animal Model of Essential Tremor.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Essential tremor (ET) is one of the most prevalent adult-onset movement disorders, which significantly impairs quality of life. So far, there are few therapeutic options with limited efficacy. This study investigated the therapeutic potential of baricitinib, a selective JAK1/2 inhibitor, in the harmaline-induced model of ET. Male Swiss mice were randomly assigned to five groups (n = 8): control, harmaline, and harmaline plus baricitinib at 10, 20, or 50 mg/kg doses. ET was induced using harmaline (10 mg/kg, i.p.). Baricitinib was administered orally daily for 14 days. Assessments included behavioral tests and cerebellar gene expression analysis of inflammatory markers (TNF-α, IL-6, NF-κB), neurotrophic factors (BDNF), ET-related targets (Lingo-1, NMDA receptor), and histopathological evaluation. Baricitinib reduced harmaline-induced tremor severity. The drug also significantly ameliorated anxiety-like behaviors in elevated plus maze and open field tests, while reducing depressive-like behavior in the tail suspension test. Passive avoidance outcomes changed in a direction suggestive of improved retention; however, the high-dose findings should be interpreted cautiously because 50 mg/kg was associated with motor coordination impairment. Molecular analyses revealed baricitinib completely normalized cerebellar pro-inflammatory cytokines TNF-α and IL-6 and suppressed NF-κB expression. The drug restored BDNF levels and reduced Lingo-1 expression. Histopathological examination also suggested reduced Purkinje cell degeneration, with 20 and 50 mg/kg doses reducing Purkinje cell degeneration to control levels. Baricitinib reduced tremor and affective behaviors in a harmaline-induced ET model, though gait abnormalities persisted. Cognitive benefits at lower doses were observed, with cautious interpretation required for the high dose due to motor effects. Molecular and histological analyses supported anti-inflammatory and neuroprotective effects, indicating selective benefits via neuroinflammatory modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.